Taysha Gene Therapies Price to Book Ratio 2020-2024 | TSHA

Historical price to book ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The current price to book ratio for Taysha Gene Therapies as of November 22, 2024 is 5.70.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Taysha Gene Therapies Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-21 2.18 5.03
2024-09-30 2.01 $0.43 4.64
2024-06-30 2.24 $0.54 4.14
2024-03-31 2.87 $0.29 9.97
2023-12-31 1.77 $0.40 4.42
2023-09-30 3.16 $-0.26 -12.03
2023-06-30 0.66 $-0.58 -1.15
2023-03-31 0.80 $-0.24 -3.39
2022-12-31 2.26 $0.02 150.67
2022-09-30 1.93 $0.27 7.14
2022-06-30 3.72 $0.80 4.67
2022-03-31 6.52 $1.32 4.95
2021-12-31 11.65 $2.48 4.70
2021-09-30 18.62 $3.65 5.10
2021-06-30 21.20 $4.86 4.36
2021-03-31 20.30 $5.90 3.44
2020-12-31 26.54 $6.66 3.99
2020-09-30 22.40 $7.09 3.16
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.506B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00